|View printer-friendly version|
|Quidel Corporation Announces Officer Resignation|
SAN DIEGO, May 30 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced the resignation of Charles J. Cashion, the Company's Chief Financial Officer, effective June 15, 2001.
Mr. Cashion is leaving to pursue other opportunities in the early stage biotechnology sector, and will be working with Quidel's senior management over the coming weeks to effect a smooth transition. Mr. Cashion noted, "It has been a great pleasure to serve on the Quidel executive team and to help build Quidel into a market leader with a quality organization. However, at this point in my career, there are other opportunities that I intend to pursue."
Andre de Bruin, Quidel's Vice Chairman and Chief Executive Officer, stated, "We thank Chuck for his contributions during the past two-and-one-half years, and we wish him the very best in his future endeavors."
The Company is currently seeking a successor to Mr. Cashion.
About Quidel Corporation
This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes (both domestically and internationally) in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.